← Leaderboards
Upendra Marathi
Plx Opco, Inc.
$8,341,809
Attributed
$16,976,361
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2008–24$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$16,976,361 · 14
By mechanism
R44$11,002,846 · 6
R42$3,866,297 · 2
R41$852,918 · 3
RC3$798,642 · 1
R43$455,658 · 2
Top collaborators
- Siddhartha De5 shared
- Lionel David Lewis4 shared
- William Schary4 shared
- Darren G Woodside4 shared
- Nisha Jain Garg3 shared
- Peter Vanderslice3 shared
- Yared Hailemichael2 shared
- Michael Schotsaert2 shared
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyDoseDrug KineticsResponseIntegrinsClinical TrialsOralFutureAnimal ModelLeadSmall MoleculePharmaceutical PreparationsCell AdhesionImmuneEffectivenessIntegrin Alpha4beta1BaseToxic EffectClinical ResearchAdultAntigen PresentationMigrationCell Adhesion MoleculesDesign
Grant awards (23)
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors$999,200
R44 · FY2024 · CA · contact PI
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$997,867
R44 · FY2024 · AI · contact PI
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$953,477
R44 · FY2024 · AI · contact PI
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors$999,200
R44 · FY2023 · CA · contact PI
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$997,867
R44 · FY2023 · AI · contact PI
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$928,224
R44 · FY2023 · AI · contact PI
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$999,300
R44 · FY2022 · AI · contact PI
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors$1,015,591
R44 · FY2021 · CA · contact PI
A small molecule integrin activator to enhance cord blood transplant$928,941
R42 · FY2021 · HL
Integrin Activation to Augment SARS-CoV-2 Vaccination$297,724
R43 · FY2021 · AI · contact PI
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors$984,409
R44 · FY2020 · CA · contact PI
A small molecule integrin activator to enhance cord blood transplant$935,957
R42 · FY2020 · HL
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$1,001,898
R42 · FY2019 · CA · contact PI
Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies$243,282
R41 · FY2019 · AI
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$999,501
R42 · FY2018 · CA · contact PI
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$313,705
R41 · FY2016 · CA · contact PI
A small molecule integrin activator to enhance cord blood transplant$295,931
R41 · FY2016 · HL
GI-Safer Formulation of Indomethacin for use in Preterm Neonates$552,949
R44 · FY2013 · HD · contact PI
GI-Safer Formulation of Indomethacin for use in Preterm Neonates$565,449
R44 · FY2012 · HD · contact PI
Clinical Evaluation of GI Safer Naproxen for the Treatment of Osteoarthritis$798,642
RC3 · FY2010 · AR · contact PI
GI-Safer Formulation of Indomethacin for use in Preterm Neonates$157,934
R43 · FY2010 · HD · contact PI
GI-Safer Naproxen Formulation R&D for the Treatment of Osteoarthritis and Related$745,708
R44 · FY2009 · AR · contact PI
GI-Safer Naproxen Formulation R&D for the Treatment of Osteoarthritis and Related$263,605
R44 · FY2008 · AR · contact PI